Research Topics
| Filip Krag KnopSummaryAffiliation: University of Copenhagen Country: Denmark Publications
| Collaborators
|
Detail Information
Publications
[The benefits of diagnostic imaging in general practice]Filip Krag Knop
Almen Praksis ved Universitetet, Bartholinsgade 6, København K
Ugeskr Laeger 168:794-8. 2006..We estimate the value of the diagnostic imaging examinations most frequently used by general practitioners and seek to evaluate their role in the primary health care system...
Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesityFilip K Knop
Department of Internal Medicine, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
Diabetes Obes Metab 14:500-10. 2012....- Small-bowel hemangiosarcoma and capsule endoscopyF K Knop
Dept. of Gastrointestinal Surgery K, H:S Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
Endoscopy 35:637. 2003 - Incretin hormones and beta cell function in chronic pancreatitisFilip Krag Knop
Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, 2900 Hellerup, Denmark
Dan Med Bull 57:B4163. 2010.... - Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?Filip K Knop
Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, Hellerup, Denmark
Am J Physiol Endocrinol Metab 299:E10-3. 2010.... - Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling?F K Knop
Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, 2900 Hellerup, Denmark
Diabetologia 52:2270-6. 2009.... - Incretin-based therapy of type 2 diabetes mellitusFilip K Knop
Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, Hellerup, Denmark
Curr Protein Pept Sci 10:46-55. 2009.... - Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibilityFilip K Knop
Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, DK 2900 Hellerup, Denmark
IDrugs 11:497-501. 2008..This feature review focuses on the challenges and feasibilities of replacing SU with incretin-based therapy in patients with T2DM... - The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose toleranceFilip K Knop
Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
Regul Pept 144:123-30. 2007..The incretin effect is reduced and the insulinotropic effect of the incretin hormone glucose-dependent insulinotropic polypeptide (GIP) is abolished in patients with type 2 diabetes mellitus (T2DM)... - [GLP-1-based treatment of type 2 diabetes mellitus]Filip Krag Knop
Vilsbøll Gentofte Hospital, Medicinsk afdeling F
Ugeskr Laeger 169:2095-9. 2007..GLP-1-based therapy results in HbA1c reductions of approximately 1 percent point, and the lack of serious side effects and the low risk of hypoglycaemic episodes are unique traits... - Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?Filip K Knop
Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Diabetes 56:1951-9. 2007..These results suggest that the reduced incretin effect is not a primary event in the development of type 2 diabetes, but rather a consequence of the diabetic state... - Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitusF K Knop
Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, DK 2900, Hellerup, Denmark
Diabetologia 50:797-805. 2007..We investigated glucagon responses during OGTT and isoglycaemic i.v. glucose infusion, respectively, to further elucidate the mechanisms behind the glucose intolerance in patients with type 2 diabetes... - Delayed ischemic cecal perforation despite optimal decompression after placement of a self-expanding metal stent: report of a caseFilip K Knop
Department of Gastrointestinal Surgery K, H S Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
Dis Colon Rectum 47:1970-3. 2004..Furthermore, we underline the need to focus on the possibility of obstructions other than those being treated... - No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitisFilip K Knop
Department of Internal Medicine F, Gentofte Hospital, Hellerup, Denmark
Diabetes Care 26:2581-7. 2003..4 +/- 1.1 according to homeostasis model assessment (HOMA). In this study, we investigated diabetic patients with normal or close to normal insulin sensitivity... - Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitutionFilip K Knop
Dept of Internal medicine F, Gentofte Hospital, Univ of Copenhagen, Niels Andersens Vej 65, DK 2900 Hellerup, Denmark
Am J Physiol Endocrinol Metab 292:E324-30. 2007..These results suggest that the secretion of GLP-1 and GIP is under influence of the digestion and absorption of nutrients in the small intestine and that PES increases insulin secretion... - KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetesKasper Aaboe
Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, Hellerup DK 2900, Denmark
J Clin Endocrinol Metab 94:603-8. 2009..With this study we therefore aimed at clarifying the role of K(ATP) channel malfunction in the impaired function of GIP... - The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotypeT Vilsbøll
Department of Internal Medicine F, Gentofte Hospital, DK 2900 Hellerup, Denmark
J Clin Endocrinol Metab 88:4897-903. 2003..In conclusion, lack of GIP amplification of the late-phase plasma insulin response to glucose seems to be a consequence of diabetes mellitus, characterizing most, if not all, forms of diabetes... - Self-expanding metal stents for colonic obstruction: experiences from 104 procedures in a single centerSøren Meisner
Department of Surgical Gastroenterology K, H S Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
Dis Colon Rectum 47:444-50. 2004..In the past, colonic obstruction caused by malignancy most often resulted in high-risk operations, usually involving two-step procedures or leaving the patient with a stoma in case of disseminated disease... - [Effect of incretin hormones GIP and GLP-1 for the pathogenesis of type 2 diabetes mellitus]Tina Vilsbøll
Gentofte Hospital, Medicinsk afdeling F, Hellerup
Ugeskr Laeger 169:2101-5. 2007..It is currently unknown whether these defects are consequences of the diabetic state or primary pathogenetic factors... - Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjectsK B Hansen
Department of Clinical Physiology, Glostrup Hospital, University of Copenhagen, Nordre Ringvej 57, DK 2600 Glostrup, Denmark
J Clin Endocrinol Metab 95:3309-17. 2010..We investigated whether reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet in healthy young males would impair the incretin effect... - Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonistsK B Hansen
Department of Clinical Physiology, Glostrup Hospital, University of Copenhagen, Nordre Ringvej, Copenhagen, Denmark
Int J Clin Pract 63:1154-60. 2009..In this review, the available data on the two drugs are presented and discussed... - Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetesP V Højberg
Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark
Diabet Med 25:1268-75. 2008..The aim of the present study was to investigate whether 4 weeks of near-normalization of blood glucose (BG) improves incretin hormone secretion and pancreatic B-cell function during a mixed meal... - Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetesP V Højberg
Department of Endocrinology, Hvidovre Hospital, Kettegaards Alle 30, DK 2650 Hvidovre, Denmark
Diabetologia 52:199-207. 2009..The aim of the present study was to investigate whether 4 weeks of near-normalisation of the blood glucose level could improve insulin responses to GIP and GLP-1 in patients with type 2 diabetes... - Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetesP V Højberg
Department of Endocrinology, Hvidovre Hospital, Kettegaards Alle 30, 2650 Hvidovre, Denmark
Diabetologia 51:632-40. 2008..We investigated whether 4 weeks of near normalisation of blood glucose (BG) improves the potentiation of glucose-stimulated insulin secretion by GLP-1... - Increased Levels of YKL-40 and Interleukin 6 in Patients With Chronic Pancreatitis and Secondary DiabetesMorten Hansen
From the Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, Hellerup Centre of Inflammation and Metabolism, Departmentof Infectious Diseases and CMRC, Rigshospitalet Departmentof Endocrinology I, Bispebjerg Hospital and Department of Endocrinology, Herlev Hospital, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
Pancreas 41:1316-8. 2012.... - The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetesAsger Lund
Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, Hellerup, Denmark
Am J Physiol Endocrinol Metab 300:E1038-46. 2011..Our results indicate that the intestinal hormones, GIP, GLP-1, and GLP-2, may play a role in the inappropriate glucagon response to orally ingested glucose in T2DM with, especially, GIP, acting to increase glucagon secretion... - Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetesEspen Jimenez-Solem
University of Copenhagen, Gentofte Hospital, Department of Internal Medicine F, Niels Andersens Vej 65, 2900 Hellerup, Denmark
Curr Opin Mol Ther 12:790-7. 2010..If dulaglutide possesses similar efficacy to other GLP-1 analogs, the once-weekly treatment will most likely be welcomed by patients with T2DM... 
The Nkx6.1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cellsJonathan C Schisler
Department of Pharmacology, Sarah W Stedman Nutrition and Metabolism Center, Durham, NC 27704, USA
Proc Natl Acad Sci U S A 102:7297-302. 2005..1 mRNA in primary rat islets was accompanied by a significant decrease in GSIS relative to control cells. In sum, our studies have revealed roles for Nkx6.1 in suppression of glucagon expression and control of GSIS in islet beta cells...